Long-Acting/Extended Release (LA/ER) Antiretroviral Research Resource Program (LEAP)
Investigator Meeting and Annual Workshop 2022
Hyatt Regency Denver
AGENDA

SATURDAY, February 12 | 1:00 AM – 5:30 PM | PLENARY SESSION | TBD

12:30 – 1:00 PM	**ONSITE REGISTRATION AND LUNCH**
1:00-1:05 PM	**Welcome:** Carl Dieffenbach, Director, Division of AIDS, NIH
1:05-1:15 PM	**Where are we LEAPing next?! –** Charles Flexner, Johns Hopkins University **Overview of Workshop –** Charles Flexner, Johns Hopkins University
	Plenary Session 1 – *Charles Flexner, Chair*
1:15-2:35 PM	**Plenary Session 1: Current Status of Existing Technologies:** **10-Minute Presentations followed by Q & A** **1:15-1:25 PM** —"Update on Transcutaneous Microneedles for Antiretroviral Drug Delivery" – **Ryan Donnelly, Queens University Belfast** **1:25-1:35 PM** —"Current status of LA/ER Cabotegravir and Rilpivirine including pipeline report on novel CBT formulations" – **William Spreen, ViiV** **1:35-1:45 PM** —"Current Status of the Merck LA/ER Pipeline" – **Jay Grobler, Merck** **1:45-1:55 PM** —"Current Status of the Gilead LA/ER Pipeline" – **Martin Rhee, Gilead Sciences** **1:55-2:05 PM** —"Open discussion on pharmaceutical pipeline" – **ViiV, Merck, Gilead** **2:05-2:15 PM** —"Update from the LEAP Modeling and Simulation Core" – **Andrew Owen, University of Liverpool** **2:15-2:25 PM** —"LEAP Systematic Reviews of LA formulation use in pediatrics and pregnancy" – **Lynn Bertagnolli, Johns Hopkins University** **2:25-2:35 PM** —"DAIDS/NIH resources to support preclinical and clinical development of ARVs and related anti-infective drugs" – **Keith Crawford, Division of AIDS, NIH**
2:35 PM-2:45	**10 Minute Break**
TIME (EST)	**Plenary Session 2 – *Andrew Owen, Chair***
2:45-4:15 PM	**Plenary Session 2: Novel approaches to LA/ER Drug Delivery:** **15-Minute Presentations followed by Q & A** **2:45-3:00 PM** —"Tenofovir implants and local toxicity: What have we learned to date?" - **Marc Baum, Oak Crest Institute** **3:00-3:15 PM** —"Developing a long-acting formulation for Hepatitis B virus treatment and prevention" **A. Chatterjee, Calibr, Scripps Institute, San Diego** **3:15-3:30 AM** — "Novel long-acting protides of approved ARVs" - **Benson Odagwa, University of Nebraska** **3:30-3:45 PM** —"Update from LONGEVITY: Novel long-acting formulations for Tuberculosis, Malaria, and Hepatitis C Virus" – **Andrew Owen, University of Liverpool** **3:45-4:00 PM** —"Update from the Targeted, Long-acting and Combination Anti-Retroviral Therapy (TLC-ART) program" – **Rodney Ho, University of Washington** **4:00-4:15 PM** —"CADO 4/PADO 5: Approach to delivery of LA ARVs for HIV Treatment and Prevention in LMICs, report from a WHO-sponsored meeting" – **David Ripin, Clinton Health Access Initiative**
4:15-4:25 PM	**10 Minute Break**

	Focus Group Summary Reports – *Sue Swindells, Chair*
4:25-5:25 PM	**10 mins for each report**
	4:25-4:35 PM Group 1: "Developing LA formulations for treatment and prevention of HBV and HDV: Where are we now and where do we need to go?" – **Andy Kaytes, UCSD**
	4:35-4:45 PM Group 2: "Long-acting oral drugs and formulations: how do they stack up compared to other routes of drug delivery" – **Polly Clayden, iBase**
	4:45-4:55 PM Group 3: "Best practices for conversion of immediate release approved ARVs: To prodrug or not to prodrug?" – **Paul Domanico, CHAI**
	4:55-5:05 PM Group 4: "Challenges in developing combination LA products and regimens?" – **Bob Bollinger, JHU**
	5:05-5:25 PM Discussion of Focus Group Reports and Next Steps – ALL
5:30 PM	**Close of Workshop**